Phase II Trial of Ixabepilone As Second-Line Treatment in Advanced Endometrial Cancer: Gynecologic Oncology Group Trial 129-P

PURPOSE: A phase II study was conducted to determine the response rate of ixabepilone (BMS-247550, National Cancer Institute (NCI)–supplied agent investigational new drug No. 59,699) in patients with persistent or recurrent endometrial cancer who have progressed despite standard therapy. PATIENTS AN...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Dizon, Don S., Blessing, John A., McMeekin, D. Scott, Sharma, Sudarshan K., DiSilvestro, Paul, Alvarez, Ronald D.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society of Clinical Oncology 2009
Gaiak:
Original Reports
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC2716935/
https://ncbi.nlm.nih.gov/pubmed/19451430
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2008.20.6995
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak